China Chinese drugmakers are increasingly looking past the NMPA toward approvals in the EU, US, and Australia. Daphne Smyth of Veristat has watched this shift from the front row, guiding sponsors through the data gaps, bridging studies, and regulatory quirks that stand between a China-developed drug and a Western marketing authorisation.…
Europe Childhood cancer survival rates in high-income countries now exceed 80 percent, but that masks a more uneven picture: paediatric drug development lags far behind adult oncology, follow-up and psychosocial care remain patchy across Europe, and survivors can face life-altering side effects that surface decades after treatment ends. Carina Schneider and…
USA Randy Pritchard, General Manager and Senior Vice President of Clinical Operations for North America at bioMérieux, a global leader in in vitro diagnostics, speaks about the outsized strategic weight of the North American market, which accounts for nearly half of the company’s global revenue and a third of its workforce.…
USA Neuroscience is back. After a litany of divestments and scale backs in the 2010s, diseases of the brain are now the second-most-funded area in biotech, behind only cancer. However, this remains a complex and challenging field, leading neuroscience biotechs – three of which are profiled below – to develop very…
Saudi Arabia Mostafa Abdelrahman, General Manager of Lilly Saudi Arabia, discusses the company’s evolution from medicine supplier to healthcare partner, supporting Vision 2030 through innovation, public-private collaboration and localisation. He highlights advances in obesity, Alzheimer’s disease and oncology, alongside technology transfer, clinical research and talent development, while outlining priorities to expand patient…
Korea Our mission has remained constant: to develop and provide cancer patients with precise treatment and early detection, and to improve patient outcomes Dr. Tae-You Kim, CEO and Co-Founder of IMBdx, discusses the company’s liquid biopsy technology, AI-driven genomic analysis and ambition to build a global precision oncology platform. He outlines…
Taiwan A genuinely healthy lifestyle can help prevent neurodegenerative disease Charles S.Y. Yang discusses how his background in physics and quantum sensing led to the founding of MagQu, pioneering ultra-sensitive blood biomarker diagnostics for Alzheimer’s and other neurodegenerative diseases. He explains the company’s SQUID-based technology, commercial journey, regulatory ambitions and funding…
MEA A quarter-century after the Human Genome Project revolutionized biology, genomic sequencing has matured from an ambitious scientific frontier into an indispensable clinical reality. Today, molecular insights routinely guide everything from targeted oncology to rare disease diagnostics. Yet, this genomic revolution harbours a profound systemic bias: nearly 90 percent of all…
Taiwan Over the past three decades, Taiwan’s elderly population – defined as individuals aged 65 and older – has expanded by a staggering 152 percent. This demographic shift has introduced complex public health challenges, most notably a sharp rise in cancer incidence. “The epidemiological picture is quite sobering,” notes John Chang,…
Taiwan Biotechnology has long been a strategic priority for Taiwan’s economic development, standing alongside ICT and semiconductors as a key pillar of growth for the island. Driven by a highly educated scientific workforce and competitive development costs, Taiwan is a natural hub for early-phase drug development and initial manufacturing. However, only…
Germany Germany’s Medical Research Act is almost two years old. Writing in the June/July 2026 edition of DIA Global Forum, Thomas Sudhop, Claudia Riedel and Karl Broich of the Federal Institute for Drugs and Medical Devices (BfArM) outline how the Act attempts to revitalise clinical research in Germany, balancing faster procedures…
Taiwan Dr. I-Shu Lee, founder and CEO of Vitae Biomedical, began his career as a postdoctoral researcher before making the uncommon leap from academic laboratory to entrepreneurship in 2019. Built around a proprietary urine-based protein detection technology for early cancer screening, Vitae Biomedical has already achieved commercial traction in Taiwan, partnering…
See our Cookie Privacy Policy Here
